Pulmonx Co. (NASDAQ:LUNG) Director Sells $157,000.00 in Stock

Pulmonx Co. (NASDAQ:LUNG) Director Glendon E. French III sold 20,000 shares of the company’s stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $7.85, for a total transaction of $157,000.00. Following the completion of the sale, the director now directly owns 991,974 shares of the company’s stock, valued at $7,786,995.90. The trade was a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Pulmonx Stock Up 0.9 %

Shares of NASDAQ:LUNG opened at $7.77 on Friday. The company has a market cap of $309.21 million, a price-to-earnings ratio of -5.40 and a beta of 0.50. Pulmonx Co. has a one year low of $5.46 and a one year high of $10.01. The firm has a fifty day moving average price of $7.14 and a two-hundred day moving average price of $6.96. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.70 and a quick ratio of 6.77.

Pulmonx (NASDAQ:LUNG) last posted its quarterly earnings data on Wednesday, February 19th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.12. The company had revenue of $23.77 million during the quarter, compared to analyst estimates of $22.29 million. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. Analysts anticipate that Pulmonx Co. will post -1.55 EPS for the current fiscal year.

Institutional Investors Weigh In On Pulmonx

Institutional investors and hedge funds have recently bought and sold shares of the stock. 272 Capital LP purchased a new position in Pulmonx in the 3rd quarter worth approximately $25,000. BNP Paribas Financial Markets bought a new stake in shares of Pulmonx during the 4th quarter worth $43,000. R Squared Ltd purchased a new position in Pulmonx in the fourth quarter worth $46,000. ProShare Advisors LLC bought a new position in Pulmonx in the fourth quarter valued at $72,000. Finally, Stifel Financial Corp bought a new position in Pulmonx in the fourth quarter valued at $81,000. 91.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on LUNG. Morgan Stanley initiated coverage on Pulmonx in a report on Monday, March 10th. They issued an “equal weight” rating for the company. Citigroup initiated coverage on Pulmonx in a research note on Monday, March 10th. They issued a “buy” rating for the company. D. Boral Capital began coverage on Pulmonx in a research note on Monday, March 10th. They set a “buy” rating and a $17.00 target price on the stock. Wells Fargo & Company cut their price target on shares of Pulmonx from $10.00 to $8.00 and set an “equal weight” rating on the stock in a report on Wednesday, December 11th. Finally, Jefferies Financial Group began coverage on shares of Pulmonx in a research report on Monday, March 10th. They issued a “buy” rating on the stock. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Pulmonx presently has a consensus rating of “Moderate Buy” and a consensus price target of $13.36.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.